Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
Top Cited Papers
- 1 February 2009
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 373 (9665) , 732-738
- https://doi.org/10.1016/s0140-6736(09)60442-6
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Dose comparison trial of sustained-release fampridine in multiple sclerosisNeurology, 2008
- Seizures in multiple sclerosisEpilepsia, 2008
- Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging studyMultiple Sclerosis Journal, 2007
- Walking capacities in multiple sclerosis measured by global positioning system odometerMultiple Sclerosis Journal, 2007
- Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatmentPharmacology & Therapeutics, 2006
- Aminopyridines for symptomatic treatment in multiple sclerosisCochrane Database of Systematic Reviews, 2002
- Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameterMultiple Sclerosis Journal, 2001
- The significant change for the Timed 25-Foot Walk in the Multiple Sclerosis Functional CompositeMultiple Sclerosis Journal, 2000
- The effect of 4‐aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo‐controlled, double‐blind, cross‐over studyAnnals of Neurology, 1992
- Rating neurologic impairment in multiple sclerosisNeurology, 1983